Clinical Trials in Uzhhorod, Zakarpattia Oblast
7 recruiting
Showing 1–6 of 6 trials
Recruiting
Phase 2
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
Malignant Neoplasm
Merck Sharp & Dohme LLC130 enrolled13 locationsNCT07252739
Recruiting
Phase 1Phase 2
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
Carcinoma, Non-Small Cell Lung
Merck Sharp & Dohme LLC450 enrolled46 locationsNCT04165070
Recruiting
KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
Carcinoma, Non-Small Cell Lung
Merck Sharp & Dohme LLC1,065 enrolled47 locationsNCT04165798
Recruiting
Phase 3
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
Rectal AdenocarcinomaColon Adenocarcinoma
Merck Sharp & Dohme LLC477 enrolled124 locationsNCT06997497
Recruiting
Phase 2
A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD
Chronic Obstructive Pulmonary Disease
Upstream Bio Inc.666 enrolled325 locationsNCT06981078
Recruiting
iCaReMe Global Registry
Heart FailureHypertensionChronic Kidney Disease+1 more
AstraZeneca35,000 enrolled55 locationsNCT03549754